Published a new study on Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy
KINETO Lab took a part in development of Bombesin-Based Peptide–Drug Conjugates, acting as drug delivery systems to safely reach the tumour environment. Two of bioconjugates revealed remarkable anti-proliferative activity, an efficient uptake by all three tested human breast and prostate cancer cell lines, high stability in plasma and a prompt release of the drug-containing metabolite by lysosomal enzymes. Moreover, they revealed a safe profile and a consistent reduction of the tumour volume in vivo.
The publication can be accessed under the following link.